Enhanced Adenoviral Vectors for Improved Immunogenicity and Stability

The present invention relates to novel adenoviral vectors with improved immunogenicity, stability, and versatility, addressing the limitations of traditional adenoviral vectors and enhancing their utility in vaccine development and gene therapy.

Traditional adenoviral vectors have limitations in terms of immunogenicity, stability, and versatility. The original patent disclosed adenoviral vectors derived from a chimpanzee adenovirus, but these vectors still have room for improvement. The present invention addresses these limitations by introducing novel adenoviral vectors with customized capsid proteins, modified E4 open reading frames, and hybrid genomes, which enhance immunogenicity, stability, and broaden the range of cell types that can be infected.

The inventive concept comprises a system of adenoviral vectors, each with a capsid from a different serotype of chimpanzee adenovirus, allowing for tailored immunogenicity and versatility. Additionally, the vectors can have modified E4 open reading frames to enhance immunogenicity. A method for generating adenoviral vectors with customized capsid proteins is also disclosed, involving the selection and modification of capsid proteins from chimpanzee adenoviruses. Furthermore, hybrid adenoviral vectors with capsids from chimpanzee adenoviruses and genomes from human adenoviruses can be created, enabling infection of a broader range of cell types. The inventive concept also encompasses methods for enhancing the stability of adenoviral vectors by identifying and modifying regions prone to degradation.

The new claims introduce novel combinations of adenoviral vector components, customized capsid proteins, and modified E4 open reading frames, which are not obvious from the original patent. The inventive concept's emphasis on tailored immunogenicity, stability, and versatility sets it apart from prior art.

Alternative embodiments of the inventive concept could include the use of different serotypes of chimpanzee adenoviruses, varying the modification of E4 open reading frames, or incorporating additional genetic elements to further enhance immunogenicity. The inventive concept could also be adapted for use in gene therapy or other applications beyond vaccine development.

The enhanced adenoviral vectors of the present invention have significant commercial potential in the vaccine development and gene therapy markets, offering improved immunogenicity, stability, and versatility. The inventive concept could be licensed to biotechnology companies, vaccine manufacturers, or research institutions, providing a competitive edge in the development of novel vaccines and gene therapies.